← Back to Search

Cytokine

PEG-rIL-29 at 180 µg for Chronic Hepatitis C (EMERGE Trial)

Phase 2
Waitlist Available
Research Sponsored by ZymoGenetics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to evaluate the safety and antiviral effects of several different doses of PEG-rIL-29 (a man-made form of IL-29) when it is given in combination with daily oral doses of ribavirin (an antiviral drug) to subjects with hepatitis C infection who have received no prior treatment for this disease.

Eligible Conditions
  • Chronic Hepatitis C

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: PEG-rIL-29 at 180 µgExperimental Treatment2 Interventions
Group II: PEG-rIL-29 at 120 µgExperimental Treatment2 Interventions
Group III: Peginterferon alfa-2a at 180 µgActive Control2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ribavirin
FDA approved

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbIndustry Sponsor
2,678 Previous Clinical Trials
4,125,045 Total Patients Enrolled
ZymoGeneticsLead Sponsor
11 Previous Clinical Trials
988 Total Patients Enrolled
Jan Hillson, MDStudy DirectorZymoGenetics
3 Previous Clinical Trials
145 Total Patients Enrolled
~39 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top